Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simultaneously working on Version 7.0 that is expected to be released early next year
Subscribe to our email newsletter
Simulations Plus has released GastroPlus Version 6.1, the latest version of its software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.
Viera Lukacova, team leader of Simulation Technologies at Simulations Plus’ said: “This new version of GastroPlus incorporates both new types of analysis as well as numerous user convenience features suggested by our worldwide user community. The simulation capability has been expanded to include dosing to the oral cavity via lingual (top of the tongue), sublingual (under the tongue), and buccal (inside the cheek) routes of administration.
“As a result of suggestions from our users, we’ve also added a long list of convenience features that help both new and experienced users to avoid common mistakes, to provide flexible units for various input data, and to extend the output options in both graphics and text formats.
Additionally, we’ve added a major improvement that affects certain low-solubility drugs by incorporating the distribution of bile salts in the intestinal tract for both fasted and fed conditions, and we’ve added the ability to estimate the improved solubility from nanoparticle formulations. Both of these solubility-related improvements provide dramatically better prediction of the dissolution rate and subsequent absorption of drugs that fall into these categories.”
The company said that Simulating these routes of administration extends the capabilities of GastroPlus into new areas with the potential of new customers, in both drug and drug delivery companies.
Simulations Plus is working on Version 7.0, which is expected to be released early next year. That version will include a comprehensive drug-drug interaction capability as well as the ocular and nasal/pulmonary administration routes that the company has been developing under its funded collaborations with major pharmaceutical companies.
Walt Woltosz, chairman and CEO of Simulations Plus, said: “Most people are aware that nitroglycerin pills are placed under the tongue where they dissolve and are absorbed. There are a number of rapid-dissolving formulations and some lingual sprays on the market that are absorbed at least partially from the oral cavity, as well as some adhesive buccal patches that stick to the inside of the cheek and release drug slowly.